Chinese solar products maker ReneSola Ltd. (ADR) (NYSE:SOL) posted its first profit in 10 quarters in the three months ended Dec. 31 and forecast higher module shipments for 2014, sending its shares up nearly 10 percent before the bell. The company forecast module shipments of 2.3-2.5 gigawatts (GW) in 2014, above the 1.73 shipped in 2013. ReneSola said it expected first-quarter module shipments of 500-520 MW, up from 326.6 MW year earlier. ReneSola Ltd. (ADR) (NYSE:SOL) shares after opening at $4.17 on last trade day and at the end of the day closed at $3.86. Company price to sales ratio in past twelve months was calculated as 0.25 and price to cash ratio as 3.64. ReneSola Ltd. (ADR) (NYSE:SOL) showed a negative weekly performance of -1.03%.
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, announced that patient dosing has begun in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The study is planned to enroll up to 16 chronic HBV patients in two dose cohorts with patients receiving either ARC-520 or placebo in combination with entecavir. The study is designed to evaluate the depth and duration of hepatitis B surface antigen (HBsAg) decline, among other measures, in response to a single dose of ARC-520. The Company anticipates planned enrollment to be complete in the second quarter of 2014 and expects top line results to be released in the third quarter. Arrowhead Research Corp (NASDAQ:ARWR) shares fell -16.09% in last trading session and ended the day on $17.37. ARWR return on equity ratio is recorded as -98.60% and its return on assets is -80.70%. Arrowhead Research Corp (NASDAQ:ARWR) yearly performance is 682.43%.
TheStreet Quant Ratings rates Endocyte, Inc. (NASDAQ:ECYT) as a sell. The company’s weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and disappointing return on equity. Endocyte, Inc. (NASDAQ:ECYT) shares moved down -3.37% in last trading session and was closed at $27.22, while trading in range of $26.75 – $30.45. Endocyte, Inc. (NASDAQ:ECYT) year to date (YTD) performance is 154.87%.
EXACT Sciences Corp. (NASDAQ:EXAS) has received an average recommendation of “Buy” from the nine brokerages that are presently covering the stock, Stock Ratings News reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $15.38. EXACT Sciences Corporation (NASDAQ:EXAS) weekly performance is 8.30%. On last trading day company shares ended up $14.22. EXACT Sciences Corporation (NASDAQ:EXAS) distance from 50-day simple moving average (SMA50) is 5.01%. Analysts mean target price for the company is $17.33.